152 related articles for article (PubMed ID: 2206633)
1. [Positron emission tomography and basal ganglia functions].
Kato M
No To Shinkei; 1990 May; 42(5):450-60. PubMed ID: 2206633
[No Abstract] [Full Text] [Related]
2. [Functional imaging for disorders of basal ganglia].
Otsuka M; Taniwaki T
Rinsho Shinkeigaku; 1999 Jan; 39(1):30-2. PubMed ID: 10377793
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography in parkinsonism.
Salmon E
Acta Neurol Belg; 1997 Sep; 97(3):187-91. PubMed ID: 9345591
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography in degenerative disorders of the dopaminergic system.
Karbe H; Holthoff V; Huber M; Herholz K; Wienhard K; Wagner R; Heiss WD
J Neural Transm Park Dis Dement Sect; 1992; 4(2):121-30. PubMed ID: 1571076
[TBL] [Abstract][Full Text] [Related]
5. Subcortical damage and cortical dysfunction in progressive supranuclear palsy demonstrated by positron emission tomography.
Karbe H; Grond M; Huber M; Herholz K; Kessler J; Heiss WD
J Neurol; 1992 Feb; 239(2):98-102. PubMed ID: 1552311
[TBL] [Abstract][Full Text] [Related]
6. High levels of dopamine activity in the basal ganglia of cigarette smokers.
Salokangas RK; Vilkman H; Ilonen T; Taiminen T; Bergman J; Haaparanta M; Solin O; Alanen A; Syvälahti E; Hietala J
Am J Psychiatry; 2000 Apr; 157(4):632-4. PubMed ID: 10739427
[TBL] [Abstract][Full Text] [Related]
7. [Functional significance of calcinosis of the basal ganglia via positron emission tomography].
Staffen W; Karbe H; Rudolf J; Herholz K; Diederich N; Heiss WD
Fortschr Neurol Psychiatr; 1994 Apr; 62(4):119-24. PubMed ID: 8206464
[TBL] [Abstract][Full Text] [Related]
8. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; Frackowiak RS
Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742
[TBL] [Abstract][Full Text] [Related]
9. Basal ganglia and frontal lobe glucose metabolism. A reproducibility positron emission tomography study.
Goldman S; Dethy S; Lotstra F; Biver F; Stanus E; Wikler D; Hildebrand J; Mendlewicz J; Luxen A
J Neuroimaging; 1995 Oct; 5(4):219-26. PubMed ID: 7579750
[TBL] [Abstract][Full Text] [Related]
10. Iodine-123-IBF SPECT evaluation of extrapyramidal diseases.
Buck A; Westera G; Sutter M; Albani C; Kung HF; vonSchulthess GK
J Nucl Med; 1995 Jul; 36(7):1196-200. PubMed ID: 7790944
[TBL] [Abstract][Full Text] [Related]
11. Gilles de la tourette syndrome: studies with the fluorine-18-labeled fluorodeoxyglucose positron emission tomographic method.
Chase TN; Foster NL; Fedio P; Brooks R; Mansi L; Kessler R; Di Chiro G
Ann Neurol; 1984; 15 Suppl():S175. PubMed ID: 6611119
[No Abstract] [Full Text] [Related]
12. Positron emission tomography.
Cohen RM; Semple WE; Gross M
Psychiatr Clin North Am; 1986 Mar; 9(1):63-79. PubMed ID: 3515332
[TBL] [Abstract][Full Text] [Related]
13. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography.
Foster NL; Gilman S; Berent S; Morin EM; Brown MB; Koeppe RA
Ann Neurol; 1988 Sep; 24(3):399-406. PubMed ID: 3265862
[TBL] [Abstract][Full Text] [Related]
14. Re: Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release.
Sakellaridis NE
Neurosurgery; 2005 Mar; 56(3):E629; author reply E629. PubMed ID: 18235260
[No Abstract] [Full Text] [Related]
15. Glucose metabolism in progressive nonfluent aphasia with and without parkinsonism.
Roh JH; Suh MK; Kim EJ; Go SM; Na DL; Seo SW
Neurology; 2010 Sep; 75(11):1022-4. PubMed ID: 20837971
[No Abstract] [Full Text] [Related]
16. Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy.
Hammes J; Bischof GN; Giehl K; Faber J; Drzezga A; Klockgether T; van Eimeren T
Mov Disord; 2017 Jan; 32(1):170-171. PubMed ID: 27476874
[No Abstract] [Full Text] [Related]
17. Progressive supranuclear palsy: loss of striatal dopamine receptors demonstrated in vivo by positron tomography.
Baron JC; Maziere B; Loc'h C; Sgouropoulos P; Bonnet AM; Agid Y
Lancet; 1985 May; 1(8438):1163-4. PubMed ID: 2860368
[No Abstract] [Full Text] [Related]
18. Positron emission tomography in hemiparkinsonism-hemiatrophy syndrome.
Przedborski S; Goldman S; Giladi N; Dhawan V; Takikawa S; Hildebrand J; Fahn S; Eidelberg D
Adv Neurol; 1993; 60():501-5. PubMed ID: 8420178
[No Abstract] [Full Text] [Related]
19. [L-18F-dopa-PET in Parkinson-plus syndromes for the detection of a disordered presynaptic dopaminergic function].
Cordes M; Snow BJ; Takahashi H; Schofield P; Cooper S; Sossi V; Morrison S; Calne DB
Nuklearmedizin; 1992 Mar; 31(2):43-7. PubMed ID: 1565570
[TBL] [Abstract][Full Text] [Related]
20. Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits.
Holthoff VA; Vieregge P; Kessler J; Pietrzyk U; Herholz K; Bönner J; Wagner R; Wienhard K; Pawlik G; Heiss WD
Ann Neurol; 1994 Aug; 36(2):176-82. PubMed ID: 8053653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
